{"id":4588,"date":"2021-05-01T12:59:00","date_gmt":"2021-05-01T10:59:00","guid":{"rendered":"https:\/\/fhu-premimpact.org\/?post_type=publication&#038;p=4588"},"modified":"2021-11-30T13:04:31","modified_gmt":"2021-11-30T12:04:31","slug":"safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2","status":"publish","type":"publication","link":"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/","title":{"rendered":"Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report"},"content":{"rendered":"\n<p>Asthma exacerbation in pregnant women is associated with obstetrical complications such as fetal growth restriction, preterm delivery and preeclampsia.\u00a0Omalizumab is a recombinant humanized monoclonal antibody approved for the treatment of severe persistent allergic asthma.\u00a0Data on its safety during pregnancy, based on case series and registries, are limited.\u00a0In this case report, we provide an assessment of omalizumab placental transfer and discussed its safety.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Allergy Asthma Immunol Res. 2021 May;13(3):515-516. doi: 10.4168\/aair.2021.13.3.515. PMID: 33733644; PMCID: PMC7984957.<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-4588","publication","type-publication","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report - FHU Prem&#039;IMPACT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report - FHU Prem&#039;IMPACT\" \/>\n<meta property=\"og:description\" content=\"Allergy Asthma Immunol Res. 2021 May;13(3):515-516. doi: 10.4168\/aair.2021.13.3.515. PMID: 33733644; PMCID: PMC7984957.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU Prem&#039;IMPACT\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-30T12:04:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/\",\"name\":\"Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report - FHU Prem&#039;IMPACT\",\"isPartOf\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\"},\"datePublished\":\"2021-05-01T10:59:00+00:00\",\"dateModified\":\"2021-11-30T12:04:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"name\":\"FHU PREM'IMPACT\",\"description\":\"Perinatal inflammation and prematurity\",\"publisher\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\",\"name\":\"FHU PREM'IMPACT\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"contentUrl\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"width\":1280,\"height\":720,\"caption\":\"FHU PREM'IMPACT\"},\"image\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.instagram.com\/fhupremimpact\/\",\"https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report - FHU Prem&#039;IMPACT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/","og_locale":"en_US","og_type":"article","og_title":"Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report - FHU Prem&#039;IMPACT","og_description":"Allergy Asthma Immunol Res. 2021 May;13(3):515-516. doi: 10.4168\/aair.2021.13.3.515. PMID: 33733644; PMCID: PMC7984957.","og_url":"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/","og_site_name":"FHU Prem&#039;IMPACT","article_modified_time":"2021-11-30T12:04:31+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/","url":"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/","name":"Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report - FHU Prem&#039;IMPACT","isPartOf":{"@id":"https:\/\/fhu-premimpact.org\/en\/#website"},"datePublished":"2021-05-01T10:59:00+00:00","dateModified":"2021-11-30T12:04:31+00:00","breadcrumb":{"@id":"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/safety-of-omalizumab-during-pregnancy-and-breast-feeding-with-assessment-of-placental-transfer-a-case-report-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhu-premimpact.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/fhu-premimpact.org\/en\/publications\/"},{"@type":"ListItem","position":3,"name":"Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report"}]},{"@type":"WebSite","@id":"https:\/\/fhu-premimpact.org\/en\/#website","url":"https:\/\/fhu-premimpact.org\/en\/","name":"FHU PREM'IMPACT","description":"Perinatal inflammation and prematurity","publisher":{"@id":"https:\/\/fhu-premimpact.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fhu-premimpact.org\/en\/#organization","name":"FHU PREM'IMPACT","url":"https:\/\/fhu-premimpact.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","contentUrl":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","width":1280,"height":720,"caption":"FHU PREM'IMPACT"},"image":{"@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/fhupremimpact\/","https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false,"twentytwenty-fullscreen":false},"uagb_author_info":{"display_name":"Laurence Lecomte","author_link":"https:\/\/fhu-premimpact.org\/en\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"Allergy Asthma Immunol Res. 2021 May;13(3):515-516. doi: 10.4168\/aair.2021.13.3.515. PMID: 33733644; PMCID: PMC7984957.","_links":{"self":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication\/4588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/media?parent=4588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}